Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 27
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Rocket Pharmaceuticals Inc
RCKT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.28
-0.01
-0.44%
Dern. MÀJ: Oct 27, 6:21 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Rocket Pharmaceuticals Financials
Rocket Pharmaceuticals (RCKT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over losses of $(0.62) per
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.04 percent. This is a 38.71 percent increase over losses of $(0.62) per share
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q3 EPS $(0.45) Beats $(0.52) Estimate
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q2 EPS $(0.62) Misses $(0.56) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.91 percent. This is a 16.22 percent increase over losses of $(0.74) per
Benzinga Newsdesk
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Avi Kapoor
